Analyst Visit Confirms Growth Potential for Boston Scientific Corporation (BSX), Buy Rating Retained

Boston Scientific Corporation (NYSE:BSX) ranks among the best medical device stocks to invest in. Following an analyst visit to Boston Scientific Corporation (NYSE:BSX)’s headquarters, TD Cowen reaffirmed its Buy rating and $115 price target on the company on October 10. According to the firm, the visit strengthened its belief in Boston Scientific’s outlook, which it had formed during the company’s most recent investor day.

Significant ground was covered in pulsed field ablation (PFA) technology during the visit, according to TD Cowen, and the firm received feedback indicating Boston Scientific Corporation (NYSE:BSX) has a “very compelling” outlook despite recent competition in the market.

The firm also cited CEO Mike Mahoney’s “thoughtful replies” to a number of growth-related questions, which underlined his emphasis on category leadership as a tactic for contracting success.

Boston Scientific Corporation (NYSE:BSX) is a global leader in the manufacture of medical devices, including stents, brain stimulation systems, heart monitors, and catheters.

While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.